Schizophrenia Trial of Aripiprazole

Otsuka Pharmaceutical Development & Commercialization, Inc.700 enrolled

Overview

Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

700

Conditions

Schizophrenia

Interventions

AripiprazoleDRUG

Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.

Olanzapine or Quetiapine or RisperidoneDRUG

Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of schizophrenia * Schizophrenia symptoms not optimally controlled or antipsychotic medication not well tolerated Exclusion Criteria: * Diagnosis of schizoaffective disorder * Patients treatment-resistant to antipsychotics

Locations (33)

Local Institution

Vienna, Austria

Outcomes

Primary Outcomes

Score on the Investigator Assessment Questionnaire at week 26

Secondary Outcomes

Clinical Global Impression scale and patient preference of medication at endpoint

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.